AngioDynamics, Inc. (ANGO) 股票分析

公司概述

AngioDynamics, Inc. operates as a specialized medical technology company dedicated to the design, manufacture, and sale of medical, surgical, and diagnostic devices primarily for treating peripheral vascular disease, as well as serving oncology and surgical settings in both the United States and international markets. The company functions within the broader Healthcare sector, specifically in the Medical Instruments & Supplies industry, a domain characterized by high regulatory standards and a focus on advancing patient care through technological innovation. In terms of scale, AngioDynamics, Inc. commands a market capitalization of $416.91M and generates annual revenue of $313.72M, while employing a workforce of 675 individuals. These valuation and revenue figures position the entity as a mid-cap player within the medical device landscape, indicating a significant operational footprint that supports its extensive product portfolio, including the Auryon Atherectomy system, without yet achieving profitability on a net income basis.

财务健康

AngioDynamics, Inc. reported total revenue of $313.72M over the trailing twelve months, yet this revenue generated a net income of -$31,387,000, revealing a substantial cost structure where expenses significantly outweighed operational earnings. The company's EBITDA stands at -$659,000, suggesting that while operating cash generation before interest and taxes is near break-even, the overall profitability remains negative. Despite the negative net income and EBITDA, the company maintains positive free cash flow of $13.94M, which indicates a degree of financial flexibility allowing for operational sustainability despite current earnings losses. The gross margin is reported at 54.3%, reflecting efficient production and pricing strategies, whereas the operating margin is -8.2% and the profit margin is -10.0%, highlighting significant overhead costs or non-operating expenses impacting the bottom line. Regarding liquidity and leverage, the company holds $37.81M in cash against $11.39M in debt, resulting in a debt-to-equity ratio of 6.57, which suggests a leveraged balance sheet structure despite the cash cushion. The current ratio of 2.35 demonstrates a robust short-term liquidity position, indicating that the company possesses more than double the current assets necessary to cover its current liabilities. Furthermore, the return on equity is -17.5% and the return on assets is -4.7%, metrics that collectively reveal that management effectiveness in generating shareholder value and utilizing assets for profit is currently hindered by the company's negative earnings position.

估值评估

Valuation metrics for AngioDynamics, Inc. present a mixed picture given the lack of positive earnings, with a trailing P/E ratio of N/A and a forward P/E of -45.86, implying that the market is pricing in a significant turnaround in expected earnings trajectory from current negative levels. The price-to-book ratio stands at 2.43, indicating that the market is valuing the company at a substantial premium over its book value, likely due to expectations of future asset appreciation or brand value despite current losses. Alternative valuation measures include a price-to-sales ratio of 1.33 and an EV/EBITDA of -598.11, suggesting that the stock is priced based on sales growth potential and asset base rather than current profitability. The stock's trading range over the last year spans a 52-week high of $13.99 and a 52-week low of $8.36, with the current price situated within this volatility band, reflecting market uncertainty regarding its path to profitability. With a beta of 0.43, the stock exhibits low price volatility relative to the broader market, meaning its price movements are less sensitive to general market fluctuations compared to larger-cap equities.

Growth & Income

AngioDynamics, Inc. has demonstrated robust revenue growth of 8.9% year-over-year, while earnings growth is N/A due to the company's negative net income, implying that top-line expansion has not yet translated into bottom-line profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are reinvested into growth initiatives rather than being distributed to shareholders. This reinvestment strategy is typical for companies in the growth phase of their lifecycle that prioritize funding R&D and market expansion over returning capital to investors. Overall, the growth and income profile of AngioDynamics, Inc. is defined by strong sales momentum in the medical device sector, offset by a complete absence of current income generation and dividend distributions.